BACKGROUND: The influence of blood pressure (BP) lowering on @entity1779 ( @entity1779 ) @entity1 is unclear. To assess the safety and efficacy of aggressive antihypertensive therapies in acute @entity1779 @entity1 , we carried out a systematic review and meta-analysis. METHODS: PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and @entity3549 database up to July 2014 were searched. High-quality randomized controlled trials were included. Low-quality trials were excluded. Serious adverse events were defined as the primary outcome. The secondary outcomes were @entity1410 ( @entity1410 ) at 24 h after onset, mortality, and favorable clinical outcome at 90 days. RESULTS: Four high-quality trials involving a total of 1427 @entity1 met the inclusion criteria and were analyzed. Odds ratios (ORs) of primary outcome was 0.96 (95% confidence interval [CI   ]: 0.82-1.13, P = 0.61). ORs of @entity1410 at 24 h after onset, mortality and favorable clinical outcome at 90 days were 0.91 (95% CI: 0.72-1.17, P = 0.47), 0.97 (95% CI: 0.79-1.20, P = 0.81), 1.13 (95% CI: 0.98-1.30, P = 0.09) respectively. CONCLUSIONS: Aggressive BP management policies are safe and might have a potency of reducing @entity1410 and improving clinical outcome.

Aggressive Blood Pressure Lowing Therapy in XXXX with Acute @entity1779 is Safe: A Systematic Review and Meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematoma enlargement', 'HE'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['ICH', 'intracerebral hemorrhage'] @entity3549 :: ('7432', 'Gene') :: ['VIP']
@entity1 :: (9606,Species) :: ['Patients']
